Sugi Predict

Sugi Predict / Compounds / SCHEMBL1797185

SCHEMBL1797185

SCHEMBL1797185

NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(NCc4cccs4)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 6/20 0.75
▸ SLC29A1 Q99808 3/20 0.75
▸ NAE1 Q13564 2/20 0.61
▸ UBA3 Q8TBC4 2/20 0.61
▸ UBA6 A0AVT1 1/20 0.61
▸ ATG7 O95352 1/20 0.61
▸ UBA7 P41226 1/20 0.61
▸ SAE1 Q9UBE0 1/20 0.61
▸ ADORA1 P30542 2/20 0.58
▸ ADORA2A P29274 1/20 0.58
▸ ADORA2B P29275 1/20 0.58
▸ DNPH1 O43598 1/20 0.58
▸ TP53 P04637 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ PAX8 Q06710 1/20 0.56
▸ NT5E P21589 1/20 0.55
▸ P2RX3 P56373 1/20 0.54
▸ P2RX2 Q9UBL9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32661607 0.92 ADORA3 (0.63) ADORA3SLC29A1NAE1UBA3UBA6
SCHEMBL1795974 0.88 ADORA3 (0.75) ADORA3SLC29A1ADORA1ADORA2AADORA2B
SCHEMBL1796735 0.87 DNPH1 (0.75) ADORA3SLC29A1NAE1UBA3UBA6
SCHEMBL17889870 0.87 DNPH1 (0.75) ADORA3SLC29A1NAE1UBA3UBA6
SCHEMBL32661872 0.86 DNPH1 (0.64) ADORA3SLC29A1NAE1UBA3UBA6
SCHEMBL1798284 0.86 NAE1 (0.61) ADORA3SLC29A1NAE1UBA3UBA6
SCHEMBL20626177 0.86 ADORA3 (1.00) ADORA3SLC29A1ADORA1ADORA2AADORA2B
SCHEMBL20626176 0.86 ADORA3 (1.00) ADORA3SLC29A1ADORA1ADORA2AADORA2B
SCHEMBL14713231 0.86 ADORA3 (1.00) ADORA3SLC29A1ADORA1ADORA2AADORA2B
SCHEMBL14713272 0.86 ADORA3 (1.00) ADORA3SLC29A1ADORA1ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2026-01-15 — — US disclosed
US-20210070798-A1 Inhibitors of E1 activating enzymes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 — — US disclosed
US-20210070798-A1 Inhibitors of E1 activating enzymes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 — — US disclosed
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. 2018-03-29 — — US disclosed
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. 2018-03-29 — — US disclosed
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. 2018-03-29 — — US disclosed
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENIUM PHARMACEUTICALS, INC. 2017-03-16 — — US disclosed
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENIUM PHARMACEUTICALS, INC. 2017-03-16 — — US disclosed
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENIUM PHARMACEUTICALS, INC. 2017-03-16 — — US disclosed
US-20160194348-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARM INC (US) 2016-07-07 — — US disclosed
EP-1848718-B1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARM INC (US) 2012-08-01 — — EP disclosed
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-09 — — US disclosed
US-7951810-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-31 — — US disclosed
US-7951810-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-31 — — US disclosed
US-7951810-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-31 — — US disclosed
EP-1848718-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-10-31 — — EP disclosed
US-20060189636-A1 Inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-08-24 — — US disclosed
WO-2006084281-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 ADORA3 1669/4885SLC29A1 1761/4885NAE1 257/4885
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 ADORA3 1669/4885SLC29A1 1761/4885NAE1 257/4885
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES ECE1, RNASE1, RCE1 ADORA3 3584/4885SLC29A1 3671/4885NAE1 41/4885
US-20160194348-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 ADORA3 1669/4885SLC29A1 1761/4885NAE1 257/4885
US-20210070798-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 ADORA3 3584/4885SLC29A1 3671/4885NAE1 41/4885
US-20060189636-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 ADORA3 3584/4885SLC29A1 3671/4885NAE1 41/4885
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF NAE1, NEDD8, UBA3 ADORA3 4387/4885SLC29A1 295/4885NAE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.